BioCardia BCDA
NASDAQ BCDA
$1.04 +0.02 (+1.96%)
At close: Oct 2, 2026 · 4:00 PM EDT

BioCardia (BCDA) Gains from Sales and Divestitures (2023)

Updated

BioCardia (BCDA) recorded Gains from Sales and Divestitures of -$8,000 in Q4 2023.

Analysis

BioCardia (BCDA) Gains from Sales and Divestitures (2023) Analysis & Trends

For FY2023, BioCardia reported Gains from Sales and Divestitures of -$4,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$19,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 BioCardia 12.58 Mn -287,001.74 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -8,000.00
API Access

BioCardia Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BCDA&period=max&api_key=YOUR_API_KEY